View Item 

Show simple item record

2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia

dc.contributor.authorKhanna, Dineshen_US
dc.contributor.authorFitzgerald, John D.en_US
dc.contributor.authorKhanna, Puja P.en_US
dc.contributor.authorBae, Sangmeeen_US
dc.contributor.authorSingh, Manjit K.en_US
dc.contributor.authorNeogi, Tuhinaen_US
dc.contributor.authorPillinger, Michael H.en_US
dc.contributor.authorMerill, Joanen_US
dc.contributor.authorLee, Susanen_US
dc.contributor.authorPrakash, Shraddhaen_US
dc.contributor.authorKaldas, Marianen_US
dc.contributor.authorGogia, Maneeshen_US
dc.contributor.authorPerez‐ruiz, Fernandoen_US
dc.contributor.authorTaylor, Willen_US
dc.contributor.authorLioté, Frédéricen_US
dc.contributor.authorChoi, Hyonen_US
dc.contributor.authorSingh, Jasvinder A.en_US
dc.contributor.authorDalbeth, Nicolaen_US
dc.contributor.authorKaplan, Sanforden_US
dc.contributor.authorNiyyar, Vandanaen_US
dc.contributor.authorJones, Danielleen_US
dc.contributor.authorYarows, Steven A.en_US
dc.contributor.authorRoessler, Blakeen_US
dc.contributor.authorKerr, Gailen_US
dc.contributor.authorKing, Charlesen_US
dc.contributor.authorLevy, Geralden_US
dc.contributor.authorFurst, Daniel E.en_US
dc.contributor.authorEdwards, N. Lawrenceen_US
dc.contributor.authorMandell, Brianen_US
dc.contributor.authorSchumacher, H. Ralphen_US
dc.contributor.authorRobbins, Marken_US
dc.contributor.authorWenger, Neilen_US
dc.contributor.authorTerkeltaub, Roberten_US
dc.date.accessioned2012-10-02T17:20:22Z
dc.date.available2013-11-04T19:53:16Zen_US
dc.date.issued2012-10en_US
dc.identifier.citationKhanna, Dinesh; Fitzgerald, John D.; Khanna, Puja P.; Bae, Sangmee; Singh, Manjit K.; Neogi, Tuhina; Pillinger, Michael H.; Merill, Joan; Lee, Susan; Prakash, Shraddha; Kaldas, Marian; Gogia, Maneesh; Perez‐ruiz, Fernando ; Taylor, Will; Lioté, Frédéric ; Choi, Hyon; Singh, Jasvinder A.; Dalbeth, Nicola; Kaplan, Sanford; Niyyar, Vandana; Jones, Danielle; Yarows, Steven A.; Roessler, Blake; Kerr, Gail; King, Charles; Levy, Gerald; Furst, Daniel E.; Edwards, N. Lawrence; Mandell, Brian; Schumacher, H. Ralph; Robbins, Mark; Wenger, Neil; Terkeltaub, Robert (2012). "2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia." Arthritis Care & Research 64(10): 1431-1446. <http://hdl.handle.net/2027.42/93740>en_US
dc.identifier.issn2151-464Xen_US
dc.identifier.issn2151-4658en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/93740
dc.publisherJohn Wiley & Sons, Inc.en_US
dc.title2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemiaen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelGeriatricsen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUniversity of Michigan, Ann Arboren_US
dc.contributor.affiliationumIHA University of Michigan Health System, Chelseaen_US
dc.contributor.affiliationotherUniversity of California, Los Angelesen_US
dc.contributor.affiliationotherUniversité Paris Diderot, Sorbonne Paris Cité, and Hôpital Lariboisière, Paris, Franceen_US
dc.contributor.affiliationotherVA Medical Center and University of Alabama, Birminghamen_US
dc.contributor.affiliationotherVA Healthcare System and University of California, San Diegoen_US
dc.contributor.affiliationotherUniversity of Auckland, Auckland, New Zealanden_US
dc.contributor.affiliationotherOklahoma Medical Research Foundation, Oklahoma Cityen_US
dc.contributor.affiliationotherVA Medical Center and New York University School of Medicine, New Yorken_US
dc.contributor.affiliationotherBoston University Medical Center, Boston, Massachusettsen_US
dc.contributor.affiliationotherRochester General Health System, Rochester, New Yorken_US
dc.contributor.affiliationotherUniversity of Otago, Wellington, New Zealanden_US
dc.contributor.affiliationotherVA Healthcare System/University of California, San Diego, 111K, 3350 La Jolla Village Drive, San Diego, CA 92161en_US
dc.contributor.affiliationotherHarvard Vanguard Medical Associates/Atrius Health, Somerville, Massachusettsen_US
dc.contributor.affiliationotherVA Medical Center and University of Pennsylvania, Philadelphiaen_US
dc.contributor.affiliationotherHospital Universitario Cruces, Vizcaya, Spainen_US
dc.contributor.affiliationotherCleveland Clinic, Cleveland, Ohioen_US
dc.contributor.affiliationotherUniversity of Florida, Gainesvilleen_US
dc.contributor.affiliationotherSouthern California Permanente Medical Group, Downeyen_US
dc.contributor.affiliationotherNorth Mississippi Medical Center, Tupeloen_US
dc.contributor.affiliationotherVeterans Affairs Medical Center, Washington, DCen_US
dc.contributor.affiliationotherEmory University, Atlanta, Georgiaen_US
dc.contributor.affiliationotherOral and Maxillofacial Surgery, Beverly Hills, Californiaen_US
dc.identifier.pmid23024028en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/93740/1/ACR_21772_sm_SupplFig2.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/93740/2/ACR_21772_sm_SupplFig4.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/93740/3/21772_ftp.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/93740/4/ACR_21772_sm_SupplFig1.pdf
dc.identifier.doi10.1002/acr.21772en_US
dc.identifier.sourceArthritis Care & Researchen_US
dc.identifier.citedreferenceSingh JA, Reddy SG, Kundukulam J. Risk factors for gout and prevention: a systematic review of the literature. Curr Opin Rheumatol 2011; 23: 192 – 202.en_US
dc.identifier.citedreferenceDesai MA, Peterson JJ, Garner HW, Kransdorf MJ. Clinical utility of dual‐energy CT for evaluation of tophaceous gout. Radiographics 2011; 31: 1365 – 75.en_US
dc.identifier.citedreferenceZhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum 2011; 63: 3136 – 41.en_US
dc.identifier.citedreferenceBhole V, de Vera M, Rahman MM, Krishnan E, Choi H. Epidemiology of gout in women: fifty‐two–year followup of a prospective cohort. Arthritis Rheum 2010; 62: 1069 – 76.en_US
dc.identifier.citedreferencePillinger MH, Goldfarb DS, Keenan RT. Gout and its comorbidities. Bull NYU Hosp Jt Dis 2010; 68: 199 – 203.en_US
dc.identifier.citedreferenceBrook RA, Forsythe A, Smeeding JE, Lawrence EN. Chronic gout: epidemiology, disease progression, treatment and disease burden. Curr Med Res Opin 2010; 26: 2813 – 21.en_US
dc.identifier.citedreferenceRoddy E, Doherty M. Epidemiology of gout. Arthritis Res Ther 2010; 12: 223.en_US
dc.identifier.citedreferenceMcAdams DeMarco MA, Maynard JW, Baer AN, Gelber AC, Young JH, Alonso A, et al. Diuretic use, increased serum urate levels, and risk of incident gout in a population‐based study of adults with hypertension: the Atherosclerosis Risk in Communities cohort study. Arthritis Rheum 2012; 64: 121 – 9.en_US
dc.identifier.citedreferenceChoi HK. A prescription for lifestyle change in patients with hyperuricemia and gout. Curr Opin Rheumatol 2010; 22: 165 – 72.en_US
dc.identifier.citedreferenceBecker MA, Schumacher HR, Benjamin KL, Gorevic P, Greenwald M, Fessel J, et al. Quality of life and disability in patients with treatment‐failure gout. J Rheumatol 2009; 36: 1041 – 8.en_US
dc.identifier.citedreferenceKhanna PP, Khanna D. Health‐related quality of life and outcome measures in gout. In: Terkeltaub R, editor. Gout and other crystal arthropathies. 1st ed. Philadelphia: Elsevier; 2011. p. 217 – 25.en_US
dc.identifier.citedreferenceSingh JA, Hodges JS, Toscano JP, Asch SM. Quality of care for gout in the US needs improvement. Arthritis Rheum 2007; 57: 822 – 9.en_US
dc.identifier.citedreferenceHarrold LR, Andrade SE, Briesacher BA, Raebel MA, Fouayzi H, Yood RA, et al. Adherence with urate‐lowering therapies for the treatment of gout. Arthritis Res Ther 2009; 11: R46.en_US
dc.identifier.citedreferenceKhanna D, Khanna PP, FitzGerald JD, Singh MK, Bae S, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 2012; 64: 1447 – 61.en_US
dc.identifier.citedreferenceNeogi T, George J, Rekhraj S, Struthers AD, Choi H, Terkeltaub RA. Are either or both hyperuricemia and xanthine oxidase directly toxic to the vasculature? A critical appraisal [review]. Arthritis Rheum 2012; 64: 327 – 38.en_US
dc.identifier.citedreferenceBrook R. The RAND/UCLA Appropriateness Method. In: McCormick KA, Moore SR, Siegel RA, editors. Methodology perspectives: AHCPR no. 95‐0009. Rockville (MD): Public Health Service; 1994. p. 59 – 70.en_US
dc.identifier.citedreferenceZhang W, Doherty M, Pascual E, Bardin T, Barskova V, Conaghan P, et al. EULAR evidence based recommendations for gout. Part I: diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1301 – 11.en_US
dc.identifier.citedreferenceZhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1312 – 24.en_US
dc.identifier.citedreferenceRomeijnders AC, Gorter KJ. Summary of the Dutch College of General Practitioners' “gout” standard. Ned Tijdschr Geneeskd 2002; 146: 309 – 13. In Dutch.en_US
dc.identifier.citedreferenceYamanaka H. Revised version of guideline for the management of hyperuricemia and gout. Nihon Rinsho 2008; 66: 643 – 6. In Japanese.en_US
dc.identifier.citedreferenceJordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 2007; 46: 1372 – 4.en_US
dc.identifier.citedreferenceStevenson M, Pandor A. Febuxostat for the management of hyperuricaemia in patients with gout: a NICE single technology appraisal. Pharmacoeconomics 2011; 29: 133 – 40.en_US
dc.identifier.citedreferenceBecker MA, Schumacher HR, Espinoza LR, Wells AF, MacDonald P, Lloyd E, et al. The urate‐lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 2010; 12: R63.en_US
dc.identifier.citedreferenceSundy JS, Baraf HS, Yood RA, Edwards NL, Gutierrez‐Urena SR, Treadwell EL, et al. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 2011; 306: 711 – 20.en_US
dc.identifier.citedreferenceChoi HK, Al‐Arfaj AM, Eftekhari A, Munk PL, Shojania K, Reid G, et al. Dual energy computed tomography in tophaceous gout. Ann Rheum Dis 2009; 68: 1609 – 12.en_US
dc.identifier.citedreferenceDalbeth N, Schauer C, MacDonald P, Perez‐Ruiz F, Schumacher HR, Hamburger S, et al. Methods of tophus assessment in clinical trials of chronic gout: a systematic literature review and pictorial reference guide. Ann Rheum Dis 2011; 70: 597 – 604.en_US
dc.identifier.citedreferenceShekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: developing guidelines. BMJ 1999; 318: 593 – 6.en_US
dc.identifier.citedreferenceHunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112: e154 – 235.en_US
dc.identifier.citedreferenceSingh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 625 – 39.en_US
dc.identifier.citedreferenceGrossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid‐induced osteoporosis. Arthritis Care Res (Hoboken) 2010; 62: 1515 – 26.en_US
dc.identifier.citedreferenceRees F, Jenkins W, Doherty M. Patients with gout adhere to curative treatment if informed appropriately: proof‐of‐ concept observational study. Ann Rheum Dis 2012. E‐pub ahead of print.en_US
dc.identifier.citedreferenceKrishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. Arthritis Rheum 2006; 54: 2688 – 96.en_US
dc.identifier.citedreferenceKrishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH. Long‐term cardiovascular mortality among middle‐aged men with gout. Arch Intern Med 2008; 168: 1104 – 10.en_US
dc.identifier.citedreferenceDalbeth N, Ames R, Gamble GD, Horne A, Wong S, Kuhn‐Sherlock B, et al. Effects of skim milk powder enriched with glycomacropeptide and G600 milk fat extract on frequency of gout flares: a proof‐of‐concept randomised controlled trial. Ann Rheum Dis 2012; 71: 929 – 34.en_US
dc.identifier.citedreferenceDessein PH, Shipton EA, Stanwix AE, Joffe BI, Ramokgadi J. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis 2000; 59: 539 – 43.en_US
dc.identifier.citedreferenceChoi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine‐rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 2004; 350: 1093 – 103.en_US
dc.identifier.citedreferenceChoi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Alcohol intake and risk of incident gout in men: a prospective study. Lancet 2004; 363: 1277 – 81.en_US
dc.identifier.citedreferenceChoi HK, Willett W, Curhan G. Fructose‐rich beverages and the risk of gout in women. JAMA 2010; 304: 2270 – 8.en_US
dc.identifier.citedreferenceChoi HK, Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ 2008; 36: 309 – 12.en_US
dc.identifier.citedreferenceZhang Y, Chen C, Choi H, Chaisson C, Hunter D, Niu J, et al. Purine‐rich foods intake and recurrent gout attacks. Ann Rheum Dis 2012. E‐pub ahead of print.en_US
dc.identifier.citedreferenceTsai YT, Liu JP, Tu YK, Lee MS, Chen PR, Hsu HC, et al. Relationship between dietary patterns and serum uric acid concentrations among ethnic Chinese adults in Taiwan. Asia Pac J Clin Nutr 2012; 21: 263 – 70.en_US
dc.identifier.citedreferenceZhang Y, Woods R, Chaisson CE, Neogi T, Niu J, McAlindon TE, et al. Alcohol consumption as a trigger of recurrent gout attacks. Am J Med 2006; 119: 800.e13 – 8.en_US
dc.identifier.citedreferenceStamp LK, Taylor WJ, Jones PB, Dockerty JL, Drake J, Frampton C, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum 2012; 64: 2529 – 36.en_US
dc.identifier.citedreferenceReinders MK, van Roon EN, Jansen TL, Delsing J, Griep EN, Hoekstra M, et al. Efficacy and tolerability of urate‐lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis 2009; 68: 51 – 6.en_US
dc.identifier.citedreferenceReinders MK, Haagsma C, Jansen TL, van Roon EN, Delsing J, van de Laar MA, et al. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients with gout. Ann Rheum Dis 2009; 68: 892 – 7.en_US
dc.identifier.citedreferenceStamp LK, O'Donnell JL, Zhang M, James J, Frampton C, Barclay ML, et al. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum 2011; 63: 412 – 21.en_US
dc.identifier.citedreferenceLupton G, Odom R. Severe allopurinol hypersensitivity syndrome. J Am Acad Dermatol 1979; 72: 1361 – 8.en_US
dc.identifier.citedreferenceArellano F, Sacristan J. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother 1993; 27: 337 – 43.en_US
dc.identifier.citedreferenceZineh I, Mummaneni P, Lyndly J, Amur S, La Grenade LA, Chang SH, et al. Allopurinol pharmacogenetics: assessment of potential clinical usefulness. Pharmacogenomics 2011; 12: 1741 – 9.en_US
dc.identifier.citedreferenceHande KR. Evaluation of a thiazide‐allopurinol drug interaction. Am J Med Sci 1986; 292: 213 – 6.en_US
dc.identifier.citedreferenceChao J, Terkeltaub R. A critical reappraisal of allopurinol dosing, safety, and efficacy for hyperuricemia in gout. Curr Rheumatol Rep 2009; 11: 135 – 40.en_US
dc.identifier.citedreferenceHande KR, Noone RM, Stone WJ. Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984; 76: 47 – 56.en_US
dc.identifier.citedreferenceSomkrua R, Eickman EE, Saokaew S, Lohitnavy M, Chaiyakunapruk N. Association of HLA‐B*5801 allele and allopurinol‐induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta‐analysis. BMC Med Genet 2011; 12: 118.en_US
dc.identifier.citedreferenceLee MH, Stocker SL, Anderson J, Phillips EJ, Nolan D, Williams KM, et al. Initiating allopurinol therapy: do we need to know the patient's HLA status? Intern Med J 2011; 42: 411 – 6.en_US
dc.identifier.citedreferenceJung JW, Song WJ, Kim YS, Joo KW, Lee KW, Kim SH, et al. HLA‐B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency. Nephrol Dial Transplant 2011; 26: 3567 – 72.en_US
dc.identifier.citedreferenceHung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, et al. HLA‐B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA 2005; 102: 4134 – 9.en_US
dc.identifier.citedreferenceTassaneeyakul W, Jantararoungtong T, Chen P, Lin PY, Tiamkao S, Khunarkornsiri U, et al. Strong association between HLA‐B*5801 and allopurinol‐induced Stevens‐Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics 2009; 19: 704 – 9.en_US
dc.identifier.citedreferenceLonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, et al, for the RegiSCAR Study Group. A European study of HLA‐B in Stevens‐Johnson syndrome and toxic epidermal necrolysis related to five high‐risk drugs. Pharmacogenet Genomics 2008; 18: 99 – 107.en_US
dc.identifier.citedreferencePerez‐Ruiz F, Hernandez‐Baldizon S, Herrero‐Beites AM, Gonzalez‐Gay MA. Risk factors associated with renal lithiasis during uricosuric treatment of hyperuricemia in patients with gout. Arthritis Care Res (Hoboken) 2010; 62: 1299 – 305.en_US
dc.identifier.citedreferenceThompson GR, Duff IF, Robinson WD, Mikkelsen WM, Galindez H. Long term uricosuric therapy in gout. Arthritis Rheum 1962; 5: 384 – 96.en_US
dc.identifier.citedreferencePineda C, Amezcua‐Guerra LM, Solano C, Rodriguez‐Henriquez P, Hernandez‐Diaz C, Vargas A, et al. Joint and tendon subclinical involvement suggestive of gouty arthritis in asymptomatic hyperuricemia: an ultrasound controlled study. Arthritis Res Ther 2011; 13: R4.en_US
dc.identifier.citedreferenceOttaviani S, Allard A, Bardin T, Richette P. An exploratory ultrasound study of early gout. Clin Exp Rheumatol 2011; 29: 816 – 21.en_US
dc.identifier.citedreferencePerez‐Ruiz F, Calabozo M, Pijoan JI, Herrero‐Beites AM, Ruibal A. Effect of urate‐lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002; 47: 356 – 60.en_US
dc.identifier.citedreferenceTakahashi S, Moriwaki Y, Yamamoto T, Tsutsumi Z, Ka T, Fukuchi M. Effects of combination treatment using anti‐hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. Ann Rheum Dis 2003; 62: 572 – 5.en_US
dc.identifier.citedreferenceReinders MK, van Roon EN, Houtman PM, Brouwers JR, Jansen TL. Biochemical effectiveness of allopurinol and allopurinol‐probenecid in previously benzbromarone‐treated gout patients. Clin Rheumatol 2007; 26: 1459 – 65.en_US
dc.identifier.citedreferenceThiele RG, Schlesinger N. Ultrasonography shows disappearance of monosodium urate crystal deposition on hyaline cartilage after sustained normouricemia is achieved. Rheumatol Int 2010; 30: 495 – 503.en_US
dc.identifier.citedreferencePerez‐Ruiz F, Hernando I, Villar I, Nolla JM. Correction of allopurinol dosing should be based on clearance of creatinine, but not plasma creatinine levels: another insight to allopurinol‐related toxicity. J Clin Rheumatol 2005; 11: 129 – 33.en_US
dc.identifier.citedreferenceBecker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353: 2450 – 61.en_US
dc.identifier.citedreferenceSchumacher HR Jr, Becker MA, Wortmann RL, MacDonald PA, Hunt B, Streit J, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis Rheum 2008; 59: 1540 – 8.en_US
dc.identifier.citedreferenceNeogi T. Clinical practice: gout. N Engl J Med 2011; 364: 443 – 52.en_US
dc.identifier.citedreferenceTerkeltaub R. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol 2010; 6: 30 – 8.en_US
dc.identifier.citedreferenceDalbeth N, Aati O, Gao A, House M, Liu Q, Horne A, et al. Assessment of tophus size: a comparison between physical measurement methods and dual‐energy computed tomography scanning. J Clin Rheumatol 2012; 18: 23 – 7.en_US
dc.identifier.citedreferenceDalbeth N, Clark B, Gregory K, Gamble G, Sheehan T, Doyle A, et al. Mechanisms of bone erosion in gout: a quantitative analysis using plain radiography and computed tomography. Ann Rheum Dis 2009; 68: 1290 – 5.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ACR_21772_sm_SupplFig2.pdf
Size:
65.52KB
Format:
PDF
View/Open
Name:
ACR_21772_sm_SupplFig4.pdf
Size:
61.10KB
Format:
PDF
View/Open
Name:
21772_ftp.pdf
Size:
850.0KB
Format:
PDF
View/Open
Name:
ACR_21772_sm_SupplFig1.pdf
Size:
82.68KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.